Is Cannabis Legal in Spain?

Possession and Private Consumption

Spain's cannabis framework is singular in the European context. Under the Spanish legal system, personal possession and consumption in private spaces has never been criminalised, a position rooted in constitutional principles of personal autonomy and the right to privacy enshrined in the Spanish Constitution of 1978. This does not mean cannabis is legal — it means the state has declined to extend the criminal law into private conduct of this nature.

Public possession and consumption are addressed by the Ley Orgánica 4/2015, commonly known as the Ley Mordaza or Citizens' Security Law, which classifies public cannabis consumption and possession as a serious administrative infraction. Fines range from €601 for minor possession to €30,000 for more substantial quantities, but no criminal record results. In practice, most public possession encounters result in fines at the lower end of this range.

The distinction between public and private space is central to how Spanish courts and prosecutors have handled cannabis cases for decades. Homes are unambiguously private. Spaces shared between consenting adults — the legal underpinning of cannabis social clubs — occupy a contested intermediate position that courts have addressed inconsistently.

Trafficking and Supply

The private consumption exemption ends absolutely at supply. Articles 368 to 378 of the Spanish Penal Code criminalise the promotion, facilitation, or supply of drugs including cannabis with penalties of one to three years for substances classed as causing serious harm to health, and three to six years for those causing less serious harm — cannabis falls into the latter category under current jurisprudence. Aggravating factors, including quantity, organised criminal enterprise, and sales to minors, attract significantly harsher penalties.

Cannabis Social Clubs

Cannabis social clubs represent Spain's most distinctive contribution to European cannabis policy debate. Typically constituted as non-profit associations, clubs allow registered adult members to collectively grow, process, and distribute cannabis to each other in a closed-circuit model that seeks to avoid the commercialisation associated with trafficking. At their peak, an estimated 800 to 1,000 clubs operated nationally, concentrated in Catalonia, the Basque Country, and Andalusia.

The legal basis for clubs rests on a combination of the private consumption doctrine and constitutional rights of association. Proponents argue that collective self-supply among private members does not constitute trafficking under the Penal Code, because there is no commercial element and consumption remains within a notionally private circle. Spanish courts have produced deeply inconsistent judgements on this question. The Supreme Court has in several rulings found that sufficiently closed and regulated clubs do not constitute drug trafficking; in other cases, applying stricter criteria, clubs have been prosecuted.

Regional Regulatory Attempts

Catalonia made the most sustained attempt to bring cannabis clubs within a formal regulatory framework, passing a regional law in 2017 that sought to establish licensing requirements, quality standards, and health protocols for clubs. The Constitutional Court suspended and ultimately partially struck down elements of the Catalan legislation, ruling that certain provisions encroached on national criminal law competence reserved to the central government. The Basque Country has similarly explored regional frameworks, with comparable constitutional obstacles.

The result in 2026 is a patchwork: clubs continue to operate under varying levels of local tolerance, ranging from Barcelona, where the club model is well established and local police exercise substantial discretion, to regions where clubs face more active enforcement. For businesses considering operating in this space, the legal uncertainty remains a significant operational and reputational risk.

Medical Cannabis

Spain's medical cannabis framework is among the most restrictive in the EU. The AEMPS (Agencia Española de Medicamentos y Productos Sanitarios) has authorised only one cannabis-based medicinal product for prescription use: Sativex (nabiximols), a mouth spray developed by GW Pharmaceuticals, approved for the symptomatic relief of spasticity in adults with multiple sclerosis. Beyond this single indication, there is no functioning CBMP prescription system in Spain.

This is a significant gap relative to peer markets. Germany, France, Italy, and the Netherlands have all developed frameworks allowing a broader range of CBMPs across multiple indications. In Spain, patients with conditions such as treatment-resistant epilepsy, chronic neuropathic pain, or chemotherapy-induced nausea have no official route to prescription cannabis. Many such patients access products through cannabis social clubs, import from other EU jurisdictions, or pay out of pocket through private online pharmacies — all of which exist in varying degrees of legal ambiguity.

There have been periodic parliamentary discussions about expanding the medical framework. A commission of inquiry in the Spanish Congress produced recommendations in 2023 that included developing a more comprehensive CBMP system, but legislative follow-through has been slow. The coalition government that emerged from the 2023 elections has not prioritised medical cannabis expansion as part of its health policy programme.

Business and the Hemp Sector

Despite its underdeveloped medical market, Spain is commercially significant in the broader European cannabis and hemp sector. The country is one of the largest hemp producers in the EU, cultivating authorised varieties with THC content not exceeding 0.3% across substantial agricultural acreage, particularly in Castile and León, Extremadura, and Andalusia. Hemp cultivation for fibre, seed, and CBD extraction has expanded as demand from European processors and consumer brands has grown.

The CBD consumer product market in Spain has followed a similar trajectory to other EU markets — rapid expansion, regulatory uncertainty, and periodic enforcement action against specific product formats (notably CBD food supplements and edibles, where Novel Food regulations create compliance complexity). Retailers and brands operating in the Spanish CBD space must navigate both national food safety law and the evolving EU harmonisation agenda.

For companies with interests in cannabis social clubs or the adult-use space, Spain offers an interesting test case for what a regulated non-commercial collective model might look like at scale, but the ongoing constitutional ambiguities make it an impractical base for scalable commercial operations without significant legal risk management.

Penalties Summary

• Private possession/use: No offence, no penalty.
• Public possession/use: Administrative fine of €601–€30,000 under the Citizens' Security Law. No criminal record.
• Cannabis cultivation (personal, private): Contested; courts apply a case-by-case analysis based on quantity and intent. Personal-scale private cultivation has been acquitted in some cases.
• Supply and trafficking: One to six years imprisonment under the Penal Code, depending on substance classification and aggravating factors. Serious aggravated cases (organised crime, minors, large quantities) attract up to nine years.
• Cannabis social club operation (if prosecuted): Treated as supply under the Penal Code in the most restrictive court rulings; acquitted under others.

2026 Outlook

Spain enters 2026 with its cannabis framework largely unchanged from 2023, and no imminent prospect of national-level structural reform. The private consumption model and the social club ecosystem continue to function, providing de facto access to cannabis for hundreds of thousands of Spanish adults — but without the regulatory scaffolding that would make this a mature, commercially investable market.

The most plausible area of development in 2026 is medical cannabis. The political cost of expanding CBMP access is lower than adult-use reform, and the clinical evidence base for conditions not currently served by Sativex is robust. If the current government were to initiate a consultation process on a broader CBMP framework, Spain could move relatively quickly — the AEMPS has the institutional capability, and EU neighbours provide ready templates.

Regional efforts to regulate social clubs will continue, but the constitutional boundaries established by the Constitutional Court make national pre-emption a persistent constraint. The most likely medium-term scenario is one in which major cities such as Barcelona maintain practical tolerance while national law remains unreformed.

Spain's hemp and CBD industry will track EU-level regulatory developments closely. Any harmonisation of CBD Novel Food status or standardisation of THC limits across member states will affect the commercial landscape for Spanish producers and retailers more directly than any domestic political shift.